What happened
LG Chem announced at its 2026 AI Bio Conference that it is integrating artificial intelligence across its new drug development process, specifically to identify biomarkers for patient selection in oncology and to predict neoantigens for personalized mRNA cancer vaccines.
LG Chem held the '2026 LG AI Bio Conference' on October 20 in Seoul, co-organized with the LG AI Research Institute and U.S. biotech venture capital firm Flagship Pioneering. The event, attended by approximately 140 officials from domestic and overseas AI bio corporations, marked the first initiative to build an AI bio innovation ecosystem centered on Korea.
The company stated it is applying AI to the entire new drug development process to raise the chances of clinical success. A primary focus is oncology, where LG Chem is using AI to analyze the biological characteristics of tumors to identify biomarkers that predict treatment response. This allows the company to select patients who are most likely to respond to specific therapies for clinical trials.
Son Ji-woong, head of LG Chem's life sciences business unit, emphasized that AI is evolving from a development tool into a core engine of competitiveness. He noted that future success depends not only on finding a structurally superior drug but also on using AI to identify the 'Right Patient' who will have strong therapeutic effects.
LG Chem is also developing an AI model to predict neoantigens for personalized mRNA cancer vaccines. Neoantigens are targets specific to cancer cells that can the immune system to recognize and attack them. The AI model analyzes the differing characteristics of each patient's cancer to find suitable neoantigens, aiming to improve the efficiency of developing personalized cancer treatments.
Source details: biz.chosun.com ↗
Why it matters
This move shifts the focus of AI in oncology from merely discovering drug candidates to optimizing clinical trial success by matching the right drug to the right patient. By using AI to analyze tumor biology and predict immune responses, LG Chem aims to reduce the high failure rates associated with cancer drug development and accelerate the timeline for personalized treatments.
Traditional cancer drug development often fails because drugs are tested on broad patient populations where only a subset may respond. By using AI to identify predictive biomarkers, LG Chem aims to streamline clinical trials by enrolling patients with a higher probability of success, potentially reducing development costs and timelines.
The application of AI to personalized mRNA vaccines represents a significant step in medicine. Instead of a one-size-fits-all approach, the AI-driven identification of neoantigens allows for vaccines tailored to the specific genetic profile of an individual's tumor, which could lead to more effective immune responses against cancer.
This initiative highlights a broader industry trend where AI is becoming central to the strategic direction of biopharmaceutical companies. The collaboration with Flagship Pioneering and presentations from companies like Insilico Medicine and Lila Science underscore the growing integration of AI agents and autonomous laboratory concepts in drug discovery and development.
Interactive Mechanism: How It Actually Works
Explore the underlying technology behind this development interactively.
crm_get_transaction(id='4092').Which component of an AI application is the machine-learning model itself?
What to watch next
Watch for the completion of preclinical studies for the AI-driven mRNA cancer vaccine platform, which LG Chem targets for next year, and the subsequent entry into full-scale clinical development in 2029.
LG Chem aims to complete preclinical studies for its AI-driven personalized mRNA cancer vaccine platform next year. The results of these studies will be critical in determining the feasibility and efficacy of the AI-predicted neoantigens.
The company plans to enter full-scale clinical development in 2029. Progress toward this milestone will indicate whether the AI-driven patient selection and vaccine design strategies are translating into viable clinical candidates.
The expansion of the AI bio innovation ecosystem in Korea, as initiated by this conference, may lead to further collaborations between domestic and global AI bio corporations, potentially accelerating the pace of AI-driven drug discovery in the region.